Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.48 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | IL2 | P60568 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12155845 | 0.94 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12156318 | 0.92 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12156304 | 0.88 | IL2 (0.56) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12156132 | 0.88 | STIM1 (0.61) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12156323 | 0.88 | SMN1; SMN2 (0.58) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12156320 | 0.87 | SMN1; SMN2 (0.51) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12155865 | 0.86 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12156310 | 0.84 | IL2 (0.47) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12241722 | 0.84 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12241669 | 0.83 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-2563776-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-11-12 | — | — | US | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | NPC1 262/4885RAB9A 1174/4885SMN1; SMN2 854/4885 |
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | NPC1 262/4885RAB9A 1174/4885SMN1; SMN2 854/4885 |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | NPC1 262/4885RAB9A 1174/4885SMN1; SMN2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.